Composite Inflammation Scoring from CRP and Biomarker Data
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical testing systems rely predominantly on C-reactive protein (CRP) for measuring inflammation, which may not correlate with other inflammatory markers in some instances, leading to incomplete assessment of health conditions.
Innovation Solution
A method and system that combines CRP levels with other inflammatory biomarker levels to generate a composite result, using a digital communication network (DCN) for community interaction, analysis, and feedback to manage health conditions effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CRP alone is used for measuring inflammation, then the testing system is simple and cost-effective, but the measurement precision is insufficient when CRP does not correlate with other inflammatory markers
Solution Approach 1:
The patent combines CRP measurement with multiple other inflammatory biomarkers (IL-6, IL-1beta, TNF-alpha, etc.) into a single comprehensive inflammation assessment system. This merging of multiple measurement functions resolves the contradiction by achieving higher measurement precision through multi-marker analysis while managing system complexity through integrated processing and interpretation frameworks.
2Reliability
If multiple inflammatory biomarkers are measured, then the inflammation assessment becomes more comprehensive and accurate, but the device complexity and testing complexity increase
Solution Approach 1:
The patent creates a universal inflammation assessment framework that can evaluate multiple biomarkers (CRP, IL-6, IL-1beta, TNF-alpha, ESR, CRP-IL6 ratio) using a single integrated system. This multi-functional approach allows the same testing platform to comprehensively assess inflammation through various markers, improving reliability while avoiding the need for separate specialized tests for each marker.
Solution Approach 2:
The patent incorporates feedback mechanisms where the results from multiple biomarkers are analyzed together to provide a comprehensive inflammation profile. The system uses the relationships between different markers (such as CRP-IL6 ratios) to feedback and refine the overall inflammation assessment, improving reliability through cross-validation of multiple measurement sources.
3Loss of information
If CRP and other inflammatory markers are combined for analysis, then a fuller perspective on inflammation is achieved, but the analysis complexity and processing requirements increase
Solution Approach 1:
The patent segments the inflammation assessment into distinct components (individual biomarker analysis, marker ratio calculations, composite scoring) that can be processed systematically. By breaking down the complex multi-marker analysis into manageable segments, the system achieves complete inflammation information while reducing the cognitive and computational load required for interpretation.
Solution Approach 2:
The patent transforms raw biomarker data into standardized parameters and composite scores that simplify analysis. By converting multiple biomarker measurements into normalized values and calculated ratios (such as CRP-IL6 ratios), the system reduces data complexity while preserving complete inflammation information, making the analysis more manageable and interpretable.
Data Source
AI summary
Methods and systems for managing an adverse health condition are provided. A digital communication network (DCN) is provided for a plurality of members of a population to interact with each other. A C-reactive protein (CRP) sample and at least one other inflammatory biomarker sample are received from an individual member. The CRP sample and the other inflammatory biomarker sample are analyzed and a CRP level and an inflammatory biomarker level are determined from the analysis. A composite result based on the CRP level and the inflammatory biomarker level is generated.